No Data
No Data
US FDA Approves Clinical Trials for Anti-Tumor Drugs by Changchun High-Tech Industry's Pharma Unit
Here's Why Changchun High-Tech Industry (Group) (SZSE:000661) Can Manage Its Debt Responsibly
The general manager of Changchun High-tech Industries (000661.SZ) has been changed to Jin Lei.
Changchun High-Tech Industries (000661.SZ) issued an announcement that the board of directors of the company recently received the company's chairman and general manager, Jiang Yun...
Express News | Changchun High-Tech Industry Says Jiang Yuntao Resigns From General Manager Post Due to 'work Arrangement'
1.3% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Changchun High-Tech Industry (Group) (SZSE:000661) Shareholders Over That Period
Changchun High-Tech Industries (000661.SZ): Insulin-Like Growth Factor I (IGF-I) detection reagent kit obtained medical instruments registration certificate.
Changchun High-tech Industries (000661.SZ) announced on August 30th that its subsidiary, Shanghai Saihuan Medical Technology Co., Ltd., has received the Medical Device Registration Certificate (In Vitro Diagnostic Reagents) from the Shanghai Municipal Drug Administration. The product, Insulin-like Growth Factor I (IGF-I) Test Kit (Fluorescence Immunoassay), is used for quantitative detection of IGF-I content in serum. This test kit can assist in the assessment of growth disorders.